US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist

1.075
+0.015+1.42%

Close Apr 26 16:00 ET

1.071
-0.004-0.38%

Post 16:15 ET

274.73MMarket Cap-1990P/E (TTM)

Adaptimmune Therapeutics Stock Forum

Trytosaveabit

Apr 12 20:14

Hmm?

$Adaptimmune Therapeutics(ADAP.US)$ Adaptimmune Therapeutics : on April 10, Unit of Co, Received Notice of Termination of Strategic Collaboration and License Agreement With Genentech

Sean Parker

Apr 6 06:26

$Adaptimmune Therapeutics(ADAP.US)$Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review.
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade.
(Type of Cancer) Synovial Sarcoma : There are more than 50 different types of soft tissue sarcomas which are categorise...

Meltyy

Apr 3 11:13

Gear up for AACR24!

See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...

Meltyy

Mar 28 19:44

Upcoming Cell & Gene Therapy PDUFA’s in 2024

Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ($Abeona Therapeutics(ABEO.US)$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ($Rocket Pharmaceuticals(RCKT.US)$ )...

Trytosaveabit

Mar 28 07:57

Nice!

$Adaptimmune Therapeutics(ADAP.US)$ Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that The Lancet published the company's pivotal Phase 2 data with afami-cel. The article, titled "SPEARHEAD-1: a single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid/round cell l...

Trytosaveabit

Mar 7 04:27

Lovin it!

$Adaptimmune Therapeutics(ADAP.US)$ At 1.72 it will be a 400% increase since 12/22! What a beautiful overall uptrend! This is the type of swing you can really sink your teeth into! Hehehe

Trytosaveabit

Feb 28 00:35

Still on a beautiful daily climb!

$Adaptimmune Therapeutics(ADAP.US)$ Nice and slow we go since late January

Trytosaveabit

Feb 7 03:21

In case you missed! Also for you to make a note!

$Adaptimmune Therapeutics(ADAP.US)$ Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review ● If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade PHILADELPHIA and OXFORD, UK, January, 31, 2024 – Adaptimmune Therapeutics plc (NASDAQ: AD...

Moomoo AI

Feb 1 21:52

Adaptimmune Therapeutics' P/S ratio remains below industry median despite share price surge. Its forecast for shrinking revenue, unlike industry peers predicting growth, justifies the low P/S ratio. Hard to foresee a strong share price rise soon under these conditions.